The ARG2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, engineered for targeted disruption of the ARG2 gene locus. This heterogeneous cell pool provides a robust loss-of-function model for interrogating arginase II biology without the selective pressures associated with clonal isolation. The polyclonal format preserves biological variability and is well suited for pooled phenotypic screening, dose?Cresponse studies, and experiments where population-level responses are desired. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, enabling stable elimination of ARG2 function across the cell population.
A-549 cells are adherent epithelial cells originally isolated from the lung adenocarcinoma tissue of a 58-year-old Caucasian male. They are a widely employed model in non-small cell lung cancer (NSCLC) research, recapitulating key features of alveolar epithelial origin, including rapid proliferation, migratory capacity, and responsiveness to inflammatory stimuli. A-549 cells retain many signaling pathways relevant to lung tumorigenesis, making them a proven platform for studying oncogenic transformation, drug resistance, and epithelial?Cmesenchymal transition. The availability of this knockout variant in an established A-549 background allows direct comparison to wild-type controls in a vast range of published experimental contexts.
ARG2 encodes the mitochondrial arginase II enzyme, which catalyzes the hydrolysis of L-arginine into urea and L-ornithine. By competing with nitric oxide synthases (NOS1/2/3) for the common substrate arginine, ARG2 reduces nitric oxide (NO) production and downstream cGMP signaling. The generated ornithine serves as a precursor for polyamine biosynthesis via ornithine decarboxylase (ODC), producing putrescine, spermidine, and spermine, and for proline synthesis via ornithine aminotransferase. ARG2 expression is transcriptionally upregulated by cytokines such as TNF-??, IL-4, and IL-13 through STAT6, NF-??B, and C/EBP?? pathways, and is modulated by hypoxia, cAMP, and PPAR??. Consequently, ARG2 is a critical node linking arginine metabolism to NO signaling, polyamine-dependent proliferation, and collagen synthesis.
In the A-549 lung adenocarcinoma context, ARG2-mediated arginine depletion contributes to immunosuppressive microenvironment formation by limiting T-cell function and promoting tumor immune evasion. ARG2 knockout is expected to elevate intracellular NO levels, attenuate polyamine pools, and potentially impair cell proliferation, migration, and anchorage-independent growth. The model therefore enables dissection of metabolic vulnerabilities in NSCLC, including the interplay between arginine flux and mTORC1 signaling. Moreover, because A-549 cells retain p53 wild-type status and key oncogenic drivers, ARG2 disruption provides a genetically defined system to explore synthetic lethal relationships and drug combination strategies targeting arginine dependency.
This product is suitable for a broad range of applications, including arginase inhibitor screening, nitric oxide quantification via Griess assay, polyamine profiling by LC-MS, and RNA-seq transcriptional profiling. It supports mechanistic studies on cytokine-induced arginase expression, immune checkpoint interplay, and metabolic reprogramming in lung cancer. Typical assays incorporate proliferation (MTT), apoptosis (Annexin V), migration (Transwell), and arginase activity measurements. Researchers can leverage these cells to explore ARG2-driven metabolic adaptation, validate downstream targets such as ornithine decarboxylase, or investigate crosstalk with the mTOR pathway. For additional technical details, please contact Ascent Research.
